> For the complete documentation index, see [llms.txt](https://docs.protoboard.xyz/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://docs.protoboard.xyz/industry-guides/medical-devices/revenue-and-reimbursement.md).
# Revenue & Reimbursement
Who pays for medical devices, how insurance and reimbursement work, common business models, and how the revenue model shapes prototype design decisions.
In consumer products, the person who buys a product is usually the person who uses it and pays for it. Medical devices split these roles across three different stakeholders, and understanding this dynamic early prevents building something clinically brilliant that nobody can afford to purchase.
This page explains enough about the business side of medical devices to inform better prototype design decisions. You do not need an MBA to build a medical device, but you do need to understand who is writing the check.
***
## The buyer / user / payer split
| Role | Who | What they care about |
| --------- | ---------------------------------------------------------------- | ----------------------------------------------------------------------- |
| **User** | Surgeon, nurse, clinician, or patient | Clinical performance, usability, outcomes, training |
| **Buyer** | Hospital, health system, procurement team | Total cost of ownership, ROI, contract terms, logistics |
| **Payer** | Insurance company, Medicare/Medicaid, or patient (out-of-pocket) | Reimbursement codes, clinical evidence of necessity, cost-effectiveness |
### Why this matters
* **The surgeon may love your device**, but the hospital CFO must justify the purchase within a fixed reimbursement payment.
* **The hospital may want to buy it**, but insurance may not cover the procedure it is used in.
* **Insurance may cover it**, but the reimbursement rate may be too low for the hospital to break even on the device cost.
A successful medical device must satisfy all three audiences. At the prototype stage, start building the economic argument alongside the clinical one.
{% hint style="info" %}
**81% of physicians surveyed could not estimate the cost of the medical implants they use regularly.** The clinician selecting your device is often unaware of its cost implications. The purchasing decision is made by a different team entirely.
{% endhint %}
***
## How reimbursement works (U.S.)
U.S. medical device reimbursement rests on three pillars. All three must be in place for a device to generate revenue.
### 1. Coding: Identifying what was done
* **CPT codes** describe the medical procedure performed (e.g., a specific surgery). These are maintained by the AMA.
* **HCPCS Level II codes** identify specific products and equipment (durable medical equipment, prosthetics, supplies). These are the codes most relevant to device manufacturers.
* **ICD-10 codes** describe the patient's diagnosis and determine which payment group applies.
### 2. Coverage: Whether it will be paid for
Even with a code, payers must determine the device is **medically necessary** for the indicated condition. Medicare makes coverage decisions through:
* **National Coverage Determinations (NCDs):** Apply nationwide
* **Local Coverage Determinations (LCDs):** Vary by region
* Commercial insurers make their own independent decisions
{% hint style="warning" %}
**"Safe and effective" (FDA's standard) is not the same as "reasonable and necessary" (CMS's coverage standard).** Many devices that receive FDA clearance still face a separate, often higher, evidentiary bar for insurance coverage. CMS may require more robust clinical data than the FDA did.
{% endhint %}
### 3. Payment: How much will be paid
| Setting | Payment mechanism | How it works |
| -------------- | --------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------- |
| **Inpatient** | DRG (Diagnosis-Related Group) | Hospital receives a fixed lump sum per admission. The device cost is bundled in; there is no separate line item for the device. |
| **Outpatient** | APC (Ambulatory Payment Classification) | Similar bundled payment for outpatient procedures. |
| **Home use** | DME Fee Schedule | Durable medical equipment has its own payment schedule. |
| **Physician** | Physician Fee Schedule | Pays the doctor separately for professional services. |
**The critical insight:** For most hospital-used devices, the device itself has no separate reimbursement. The hospital absorbs the cost within a fixed payment for the entire episode of care. If your device costs more than the DRG or APC payment allows, the hospital loses money on every case.
***
## Getting a new device reimbursed
If no existing code covers your device, the process takes years:
{% stepper %}
{% step %}
#### Check for existing codes
Many new devices can be billed under existing CPT or HCPCS codes. If your device is used in a procedure that already has a code, no new code may be needed.
{% endstep %}
{% step %}
#### Apply for a new HCPCS code
Submissions to CMS happen twice a year (January and July deadlines). CMS publishes preliminary decisions, holds public meetings, and issues final decisions. Timeline: **12-24 months** from application to active code, often longer.
{% endstep %}
{% step %}
#### Secure coverage
Demonstrate the device is "reasonable and necessary." This often requires more clinical evidence than the FDA required. A single clinical trial is rarely sufficient for payers.
{% endstep %}
{% step %}
#### Achieve adequate payment
Even with a code and coverage, the payment rate must make the device economically viable for hospitals to adopt.
{% endstep %}
{% endstepper %}
### Special pathways for novel devices
| Pathway | What it does | Who qualifies |
| ---------------------------------------------------------- | ----------------------------------------------------------------------------- | ---------------------------------------------------------------------- |
| **NTAP** (New Technology Add-On Payment) | Supplemental inpatient payment on top of the DRG | Costly new technologies that are inadequately paid under existing DRGs |
| **Transitional Pass-Through** | Temporary separate outpatient payment for 2-3 years | Novel devices under the Hospital Outpatient system |
| **TCET** (Transitional Coverage for Emerging Technologies) | Expedited Medicare coverage, goal of NCD within 6 months of FDA authorization | FDA-designated Breakthrough Devices (up to 5 per year) |
***
## The "valley of death"
The period between FDA clearance and commercial viability kills many device companies.
**The core problem:** Cleared medical devices based on novel technologies take an average of **5.7 years** to achieve Medicare coverage. During those years, the company needs revenue to survive but cannot generate it without reimbursement.
### Why it happens
* **Reimbursement gap:** FDA clearance and payer coverage are separate processes with different evidence requirements and timelines.
* **Funding gap:** Investors fund through FDA clearance and then expect revenue. But revenue requires reimbursement, which takes years.
* **Misaligned clinical evidence:** Clinical trials designed for FDA may not satisfy CMS, which often requires data from Medicare-age populations.
* **Commercialization complexity:** Hospital sales involve GPOs, value analysis committees, and procurement processes that engineering-driven startups underestimate.
### How to avoid it
* **Start reimbursement planning 18-24 months before anticipated FDA clearance**, not after.
* **Design clinical trials that satisfy both FDA and CMS.** Include Medicare-age patients and endpoints that payers care about.
* **Engage payers early.** The FDA has an Early Payor Feedback Program.
* **Understand your reimbursement pathway before finalizing device design.** The target payment mechanism should influence design decisions.
***
## Common business models
The business model you choose directly affects how your prototype should be designed and built.
### Capital equipment
**Model:** Hospital buys the device outright for a large upfront price.
**Examples:** MRI machines, surgical robots, hospital beds.
**Design implication:** Must be durable, serviceable, and have a long useful life (7-10+ years) to justify the investment. Modular design enables upgrades without full replacement.
### Consumables / disposables (razor-and-blade)
**Model:** Sell the capital platform at modest margin, generate recurring revenue from disposable components required for each use.
**Examples:** Intuitive Surgical's da Vinci system: the robot sells for $500K-$2M (\~15% of revenue), but single-use instruments at \~$1,800 per procedure account for \~61% of total revenue across 2.7 million annual procedures.
**Design implication:** The disposable's cost of goods sold is the key profit driver. Material selection, injection-moldability, and per-unit manufacturing cost matter enormously. Design the interface between platform and consumable to be proprietary.
### SaaS / software components
**Model:** Recurring subscription for software: analytics, AI diagnostics, remote monitoring, software updates.
**Examples:** Connected patient monitors with cloud analytics, AI-assisted imaging interpretation.
**Design implication:** Design in connectivity (Bluetooth, Wi-Fi, cellular), sensors, and secure data transmission from the prototype stage. The hardware may be a loss leader for software revenue. Converts hospital spending from capital expenditure (CAPEX) to operational expenditure (OPEX), which many hospitals prefer.
### Per-procedure / pay-per-use
**Model:** Hospital pays only when the device is used, aligning cost with utilization.
**Design implication:** Reliability and uptime are critical; downtime directly reduces revenue. Usage tracking must be built into the device to automate billing.
Outcome-based and risk-sharing models
An emerging model where payment is tied to clinical results. If the device reduces complications or improves recovery, the manufacturer receives full payment. If outcomes fall short, the hospital receives a rebate.
**Design implication:** Requires measurable outcome data, which means sensors, connectivity, and data collection must be designed in from the start.
***
## How the business model shapes your prototype
These are not abstract business decisions; they directly affect physical design choices you make during prototyping.
### Disposable vs. reusable
| Factor | Disposable | Reusable |
| ------------------------ | ---------------------------------------- | ------------------------------------------------ |
| **Materials** | Commodity plastics, lower-grade polymers | Surgical steel, ceramics, medical-grade polymers |
| **Sterilization** | Survives one cycle (EO, radiation) | Survives hundreds of cycles (autoclave at 134C) |
| **Manufacturing target** | Low per-unit cost at high volume | Higher per-unit cost, fewer units |
| **Revenue model** | Recurring consumable sales | One-time or lease payment |
Many successful devices use a **hybrid approach**: a reusable handle/platform with disposable tips or cartridges. This is where the razor-and-blade model directly dictates mechanical architecture.
### Work backwards from reimbursement
Before finalizing your design, determine:
1. **What procedure will this device be used in?**
2. **What DRG or APC covers that procedure?**
3. **What does the hospital get paid?**
4. **What can the hospital afford to spend on your device within that payment?**
This gives you your **target selling price**. From there, work backwards to your target cost of goods:
* **Disposables:** COGS typically 20-30% of selling price
* **Capital equipment:** Higher margins, but longer sales cycles
{% hint style="info" %}
**Roughly 80% of a product's cost is locked in during the design phase.** A prototype that works beautifully but cannot be manufactured at the target COGS for your intended business model is commercially dead. Consider cost constraints from day one.
{% endhint %}
### Build in data collection early
Even if your V1 prototype does not need connectivity, design the architecture to accommodate sensors and data transmission. Outcome data is increasingly required by payers and gives you optionality for SaaS or outcome-based models later.
***
## Hospital purchasing: who you actually sell to
### Group Purchasing Organizations (GPOs)
Over 95% of U.S. hospitals use GPOs (Vizient, Premier, HealthTrust, Intalere) to negotiate pricing. GPO contracts account for about 70% of a hospital's non-labor purchases.
**If you are not on a GPO contract, most hospitals cannot easily buy your product.** Getting on contract requires demonstrated clinical value, competitive pricing, and often existing market traction. This is a significant barrier for startups.
### Value Analysis Committees (VACs)
The internal hospital gatekeepers. Cross-functional committees (12-24 members) including physicians, nurses, supply chain, administrators, and finance.
**A surgeon loving your device is necessary but not sufficient.** You must also convince the supply chain team, the finance team, and the nursing staff. Clinical evidence (peer-reviewed studies, real-world data) is essential; anecdotal physician endorsements alone will not pass a modern VAC.
The typical path from first contact to first purchase order: **6-18 months** for disposables, potentially longer for capital equipment.
***
## International market differences
If you plan to sell outside the U.S., payment systems work differently.
United Kingdom (NHS / NICE)
Single-payer system funded by taxation. All residents receive care free at point of use. The National Institute for Health and Care Excellence (NICE) evaluates technologies against explicit cost-effectiveness thresholds, generally 20,000-30,000 GBP per Quality-Adjusted Life Year (QALY). Without a positive NICE assessment, widespread NHS adoption is very difficult.
**Key difference:** No insurance negotiation. The NHS is the single purchaser. Reimbursement is procedure-based (Healthcare Resource Groups), not device-specific. Doctors are salaried with no fee-for-service incentive.
Germany, France, and Japan
**Germany:** Statutory health insurance with multiple competing "sickness funds." Uses a DRG-like system (G-DRG). Novel high-risk devices may require additional clinical studies before full reimbursement.
**France:** Aggressive national price negotiation. Novel devices can receive temporary reimbursement through innovation-specific pathways while long-term evidence is gathered.
**Japan:** Universal health insurance with device pricing benchmarked against the average of prices in the U.S., UK, France, Germany, and Australia. The Japanese price cannot exceed 1.25x the adjusted foreign average.
{% hint style="info" %}
**Practical takeaway:** International markets generally have more centralized pricing authority and explicit cost-effectiveness requirements. A device commercially viable in the U.S. is not automatically viable internationally. If you plan to sell globally, factor Health Technology Assessment requirements into your evidence generation strategy early.
{% endhint %}
***
## What to think about at the prototype stage
You do not need a full commercial strategy during a hackathon or early prototyping. But keeping these questions in mind leads to better design decisions:
1. **Who is the user, who is the buyer, and who is the payer?** If they are different people with different priorities, your design needs to satisfy all three.
2. **Is this single-use or reusable?** This affects materials, sterilization, manufacturing, and your entire revenue model.
3. **What does the hospital get paid for the procedure?** This caps what they can spend on your device.
4. **Does a reimbursement code exist?** If not, add 1-2 years (minimum) to your commercialization timeline.
5. **Could this device generate data?** Connectivity and data collection add cost to the prototype but open higher-value business models.
{% hint style="success" %}
**Bottom line:** The medical revenue model is complicated, but the core question is simple: **Can the hospital afford to use your device within what insurance pays them?** If yes, you have a viable product. If no, the design needs to change: either the cost comes down, or the clinical value must be high enough to justify a premium.
{% endhint %}
***
## Related pages
* [FDA Regulatory Pathways](/industry-guides/medical-devices/fda-regulatory-pathways.md): Classification, clearance, and marketing rules
* [Manufacturing Standards & Certifications](/industry-guides/medical-devices/manufacturing-standards.md): How standards affect production costs
* [Projects](/user-guide/projects.md): Setting up your Protoboard project
* [BOM + Export](/user-guide/bom-and-export.md): Exporting your bill of materials for sourcing
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://docs.protoboard.xyz/industry-guides/medical-devices/revenue-and-reimbursement.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.